The Immune System – Products

PCR/qPCR solution will support surveillance and monitoring of the current H5N1 strain of bird flu in response to multi-state outbreak in U.S. dairy cows.

AMP published a set of evidence-based recommendations for the analytical validation and reporting of tumor mutational burden (TMB) testing as a potential predictive biomarker for immune checkpoint inhibitor (ICI) therapies.

Partnership addresses biopharmaceutical industry’s urgent need for improved in-process and QC testing tools for these rapidly evolving application fields.

This whitepaper explores groundbreaking organ-on-a-chip technology and 3D tissue modeling that is closing the translational gap in cancer drug discovery.

At the 72nd ASMS meeting, Bruker Corporation (Nasdaq: BRKR) launches the new top-of-the-line timsTOF Ultra 2 system with significantly further enhanced sensitivity for deep profiling of small cells and subcellular organelles.

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy (CAR-T cell therapy) for patients in Estonia.

Sino Biological offers a wide range of recombinant CD2 and CD58 proteins and antibodies to support elucidating key interactions and pathways and shedding light on potential therapeutic strategies.

Plasma-based proteomic platform predicts clinical benefit from immune-checkpoint inhibitors in NSCLC, melanoma, and HPV-related cancers.

Fluidic Sciences Ltd., announces its official launch as a company, and the commercial relaunch of the acquired Fluidity One-M instrument for measuring protein-protein interactions in solution—leveraging Microfluidic Diffusional Sizing (MDS) technology.

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering.